Approval of study design by French ANSM and Ethics Committee Recruitment of 12 patients expected to start in Q4 2023 in 4 French centers First study results expected in mid-2024 Endocarditis is an ...
NANTES, France--(BUSINESS WIRE)--Regulatory News: Pherecydes Pharma (FR0011651694 - ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated ...
Deferring antibiotic initiation until blood culture results are available is not linked to worse mortality or clinical ...
YONKERS, N.Y., Feb. 24, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), ...
This is a preview. Log in through your library . Abstract This study compared the promoter activation profiles of the 2 major transcripts of the Staphylococcus aureus global regulon, agr (RNAII and ...
Patients in stable condition who had endocarditis on the left side of the heart caused by streptococci, Enterococcus faecalis, Staphylococcus aureus, or coagulase-negative staphylococci were randomly ...
Mechanical vacuum aspiration to debulk lead-associated vegetations during lead extraction appears feasible and safe and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback